Innovation Pharmaceuticals Stock Key Fundamental Indicators
| IPIX Stock | USD 0 0.0003 42.86% |
As of the 11th of February 2026, Innovation Pharmaceuticals retains the Risk Adjusted Performance of 0.1821, downside deviation of 43.12, and Market Risk Adjusted Performance of (8.23). Innovation Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Innovation Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Innovation Pharmaceuticals' valuation are provided below:Innovation Pharmaceuticals does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Innovation |
Innovation Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innovation Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innovation Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Innovation Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Innovation Pharmaceuticals or generate 0.0% return on investment in Innovation Pharmaceuticals over 90 days. Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat ... More
Innovation Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innovation Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innovation Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 43.12 | |||
| Information Ratio | 0.2137 | |||
| Maximum Drawdown | 438.24 | |||
| Value At Risk | (52.38) | |||
| Potential Upside | 142.86 |
Innovation Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innovation Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innovation Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Innovation Pharmaceuticals historical prices to predict the future Innovation Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1821 | |||
| Jensen Alpha | 15.1 | |||
| Total Risk Alpha | 7.77 | |||
| Sortino Ratio | 0.3449 | |||
| Treynor Ratio | (8.24) |
Innovation Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1821 | |||
| Market Risk Adjusted Performance | (8.23) | |||
| Mean Deviation | 38.56 | |||
| Semi Deviation | 23.08 | |||
| Downside Deviation | 43.12 | |||
| Coefficient Of Variation | 464.99 | |||
| Standard Deviation | 69.58 | |||
| Variance | 4841.68 | |||
| Information Ratio | 0.2137 | |||
| Jensen Alpha | 15.1 | |||
| Total Risk Alpha | 7.77 | |||
| Sortino Ratio | 0.3449 | |||
| Treynor Ratio | (8.24) | |||
| Maximum Drawdown | 438.24 | |||
| Value At Risk | (52.38) | |||
| Potential Upside | 142.86 | |||
| Downside Variance | 1859.13 | |||
| Semi Variance | 532.81 | |||
| Expected Short fall | (94.38) | |||
| Skewness | 3.0 | |||
| Kurtosis | 10.83 |
Innovation Pharmaceuticals Backtested Returns
Innovation Pharmaceuticals is out of control given 3 months investment horizon. Innovation Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.22, which attests that the entity had a 0.22 % return per unit of risk over the last 3 months. We were able to collect and analyze data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 15.61% are justified by taking the suggested risk. Use Innovation Pharmaceuticals Market Risk Adjusted Performance of (8.23), risk adjusted performance of 0.1821, and Downside Deviation of 43.12 to evaluate company specific risk that cannot be diversified away. Innovation Pharmaceuticals holds a performance score of 17 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -1.82, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Innovation Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Innovation Pharmaceuticals is expected to outperform it. Use Innovation Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and price action indicator , to analyze future returns on Innovation Pharmaceuticals.
Auto-correlation | -0.03 |
Very weak reverse predictability
Innovation Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between Innovation Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innovation Pharmaceuticals price movement. The serial correlation of -0.03 indicates that only 3.0% of current Innovation Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.03 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Innovation Pharmaceuticals has an Operating Margin of -339.8333%. This is much higher than that of the Biotechnology sector and 203.23% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Innovation Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innovation Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Innovation Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innovation Pharmaceuticals competition to find correlations between indicators driving Innovation Pharmaceuticals's intrinsic value. More Info.Innovation Pharmaceuticals is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Innovation Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Innovation Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Innovation Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovation Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovation Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Innovation Pharmaceuticals by comparing valuation metrics of similar companies.Innovation Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Innovation Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (339.83) % | |||
| Current Valuation | 7.56 M | |||
| Shares Outstanding | 488.32 M | |||
| Shares Owned By Insiders | 10.10 % | |||
| Price To Earning | (7.57) X | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 557.16 X | |||
| Revenue | 18 K | |||
| Gross Profit | 18 K | |||
| EBITDA | (6.54 M) | |||
| Net Income | (7.04 M) | |||
| Cash And Equivalents | 2.97 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.24 M | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 0.60 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (6.28 M) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | 0.18 | |||
| Market Capitalization | 9.52 M | |||
| Total Asset | 10.38 M | |||
| Retained Earnings | (87.38 M) | |||
| Working Capital | 44.72 K | |||
| Current Asset | 529.15 K | |||
| Current Liabilities | 484.43 K | |||
| Z Score | -7.0 | |||
| Net Asset | 10.38 M |
About Innovation Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovation Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovation Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovation Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.